Jump Financial LLC Acquires Shares of 56,780 Protagonist Therapeutics, Inc. $PTGX

Key Points

• Jump Financial LLC acquired a new position in Protagonist Therapeutics, purchasing 56,780 shares worth approximately $2.75 million, which represents about 0.09% of the company's stock.
• Protagonist Therapeutics received positive analyst ratings, with a price target raised from $67.00 to $69.00, and currently holds a consensus rating of "Buy" with a target price of $67.20.
• CEO Dinesh V. Patel sold 22,065 shares at an average price of $55.05, contributing to a total insider sale of $4.02 million in the last quarter.

Jump Financial LLC purchased a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 56,780 shares of the company's stock, valued at approximately $2,746,000. Jump Financial LLC owned 0.09% of Protagonist Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. GAMMA Investing LLC grew its holdings in shares of Protagonist Therapeutics by 153.3% in the 1st quarter. GAMMA Investing LLC now owns 1,203 shares of the company's stock worth $58,000 after acquiring an additional 728 shares during the period. Smartleaf Asset Management LLC lifted its stake in Protagonist Therapeutics by 141.7% in the 1st quarter. Smartleaf Asset Management LLC now owns 1,211 shares of the company's stock valued at $59,000 after buying an additional 710 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in Protagonist Therapeutics in the 4th quarter valued at approximately $48,000. Brooklyn Investment Group purchased a new stake in Protagonist Therapeutics in the 1st quarter valued at approximately $68,000. Finally, PNC Financial Services Group Inc. lifted its stake in Protagonist Therapeutics by 38.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,992 shares of the company's stock valued at $96,000 after buying an additional 551 shares in the last quarter. Institutional investors and hedge funds own 98.63% of the company's stock.

Protagonist Therapeutics Stock Performance

Protagonist Therapeutics stock traded up $0.91 during trading on Friday, hitting $59.05. The company's stock had a trading volume of 792,267 shares, compared to its average volume of 657,634. The stock has a market capitalization of $3.67 billion, a price-to-earnings ratio of 84.36 and a beta of 2.33. The stock's fifty day moving average is $54.58 and its 200 day moving average is $49.23. Protagonist Therapeutics, Inc. has a 1-year low of $33.31 and a 1-year high of $61.89.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.02). The firm had revenue of $5.55 million during the quarter, compared to analysts' expectations of $8.32 million. Protagonist Therapeutics had a return on equity of 8.12% and a net margin of 24.88%. On average, research analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on PTGX shares. JMP Securities upped their target price on Protagonist Therapeutics from $67.00 to $69.00 and gave the company a "market outperform" rating in a research note on Thursday, August 7th. Wall Street Zen raised Protagonist Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, June 8th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Protagonist Therapeutics in a research note on Tuesday, June 3rd. Finally, Citigroup reaffirmed an "outperform" rating on shares of Protagonist Therapeutics in a research note on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $67.20.

Insider Buying and Selling

In related news, Director William D. Waddill sold 4,000 shares of the stock in a transaction on Wednesday, August 27th. The stock was sold at an average price of $59.25, for a total value of $237,000.00. Following the transaction, the director directly owned 9,130 shares of the company's stock, valued at approximately $540,952.50. This trade represents a 30.46% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Arturo Md Molina sold 10,000 shares of the stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $57.03, for a total value of $570,300.00. Following the completion of the transaction, the insider directly owned 83,892 shares in the company, valued at $4,784,360.76. This trade represents a 10.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 76,859 shares of company stock valued at $4,257,877. 4.90% of the stock is currently owned by company insiders.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.